JP7344269B2 - タバコ嗜癖性の低下用の経口組成物 - Google Patents
タバコ嗜癖性の低下用の経口組成物 Download PDFInfo
- Publication number
- JP7344269B2 JP7344269B2 JP2021202524A JP2021202524A JP7344269B2 JP 7344269 B2 JP7344269 B2 JP 7344269B2 JP 2021202524 A JP2021202524 A JP 2021202524A JP 2021202524 A JP2021202524 A JP 2021202524A JP 7344269 B2 JP7344269 B2 JP 7344269B2
- Authority
- JP
- Japan
- Prior art keywords
- oral composition
- tobacco addiction
- smoking
- nicotine
- reducing tobacco
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000208125 Nicotiana Species 0.000 title claims description 57
- 235000002637 Nicotiana tabacum Nutrition 0.000 title claims description 57
- 206010012335 Dependence Diseases 0.000 title claims description 49
- 239000000203 mixture Substances 0.000 title claims description 48
- 230000001603 reducing effect Effects 0.000 title claims description 36
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical class CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 55
- 230000000391 smoking effect Effects 0.000 claims description 52
- 229960002715 nicotine Drugs 0.000 claims description 29
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 29
- 210000002700 urine Anatomy 0.000 claims description 28
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 24
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 24
- 239000004480 active ingredient Substances 0.000 claims description 8
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 claims description 5
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 claims description 5
- XGCCBKJIKOMKRR-UHFFFAOYSA-N Hydroxy-cotinin Natural products CN1C(C(O)CC1=O)c1cccnc1 XGCCBKJIKOMKRR-UHFFFAOYSA-N 0.000 claims description 5
- 229950006073 cotinine Drugs 0.000 claims description 5
- 239000000779 smoke Substances 0.000 claims description 5
- XOKCJXZZNAUIQN-DTWKUNHWSA-N trans-3-hydroxycotinine Chemical compound C1[C@@H](O)C(=O)N(C)[C@@H]1C1=CC=CN=C1 XOKCJXZZNAUIQN-DTWKUNHWSA-N 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 4
- 238000009256 replacement therapy Methods 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 230000001332 colony forming effect Effects 0.000 claims description 3
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 238000011282 treatment Methods 0.000 description 39
- 241000186660 Lactobacillus Species 0.000 description 17
- 229940039696 lactobacillus Drugs 0.000 description 17
- 230000007423 decrease Effects 0.000 description 15
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000002775 capsule Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 235000019504 cigarettes Nutrition 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 206010012374 Depressed mood Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 230000005586 smoking cessation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- -1 inhalers Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940124811 psychiatric drug Drugs 0.000 description 1
- 101150037928 recN gene Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Description
下記の添付図面についての詳細な説明は、本発明の上記及び他の目的、特徴、メリットと実施例をより分かりやすくするためのものである。
実施例1、菌株由来及び調製
実施例2、発酵乳酸桿菌GKF3のタバコ嗜癖性に対する低下効果を、生理学的検出数値で評価する
(1)重大な精神疾患を有するもの、
(2)抗生物質服用者、
(3)高度なアルコール嗜癖又は本試験結果に影響を与える他の行為を持つもの、
(4)精神薬物を服用しているもの(例えば、抗鬱薬)、
(5)ニコチン関連の補充療法を受けたことがある又は受けているもの、
(6)3ヶ月前又はプロバイオティクスを使用しているもの。
実施例3、発酵乳酸桿菌GKF3のタバコ嗜癖性に対する低下効果を、認知尺度によって評価する
発酵乳酸桿菌GKF3は、中国一般微生物株保存管理センター(China General Microbiological Culture Collection Center;CGMCC、アドレス:北京市朝陽区北辰西路1号院3号、中国科学院微生物研究所、郵便番号:100101)に寄託され、寄託日期が2018年1月12日であり、且つ受託番号がCGMCC 15203である。
110、115、120、130、140、145、150、210、215、220、230、240、245、250:工程
401、403:縦棒
Claims (10)
- ニコチン関連の補充療法を受けたことがある又は受けているものを除く喫煙被験者の尿のニコチン代謝物質の含有量を低下させるためのタバコ嗜癖性の低下用の経口組成物であって、前記経口組成物の有効成分が、有効用量の発酵乳酸桿菌(Lactobacillus fermentum)GKF3からなり、前記発酵乳酸桿菌GKF3は、2018年1月12日に中国一般微生物株保存管理センター(China General Microbiological Culture Collection Center;CGMCC)に寄託され、受託番号がCGMCC 15203である、タバコ嗜癖性の低下用の経口組成物。
- 前記経口組成物を投与されていない前記喫煙被験者に比べると、前記経口組成物を投与された前記喫煙被験者の前記尿の前記ニコチン代謝物質の前記含有量は、10ng/mL~1100ng/mL低下する請求項1に記載のタバコ嗜癖性の低下用の経口組成物。
- 前記ニコチン代謝物質は、コチニン及び/又はトランス3-ヒドロキシコチニンを含む請求項1に記載のタバコ嗜癖性の低下用の経口組成物。
- 前記有効用量は、700mg/60kg・体重(body weight;bw)/日間~900mg/60kg・bw/日間である請求項1に記載のタバコ嗜癖性の低下用の経口組成物。
- 前記経口組成物は、前記喫煙被験者に、25日間~30日間である投与時間をかけて投与される請求項4に記載のタバコ嗜癖性の低下用の経口組成物。
- タバコ嗜癖性の低下用の経口組成物であって、前記経口組成物の有効成分が、有効用量の発酵乳酸桿菌GKF3(受託番号:CGMCC 15203)からなり、且つニコチン関連の補充療法を受けたことがある又は受けているものを除く喫煙被験者に対する前記有効用量が毎日700mg/60kg・bw/日間~900mg/60kg・bw/日間であるタバコ嗜癖性の低下用の経口組成物。
- 前記経口組成物は、前記喫煙被験者の尿のニコチン代謝物質の含有量を低下させる請求項6に記載のタバコ嗜癖性の低下用の経口組成物。
- 前記経口組成物を投与されていない前記喫煙被験者に比べると、前記経口組成物を投与された前記喫煙被験者の前記尿の前記ニコチン代謝物質の前記含有量は、10ng/mL~1100ng/mL低下する請求項7に記載のタバコ嗜癖性の低下用の経口組成物。
- タバコ嗜癖性の低下用の経口組成物であって、前記経口組成物の有効成分が、有効用量の発酵乳酸桿菌GKF3(受託番号:CGMCC 15203)からなり、且つニコチン関連の補充療法を受けたことがある又は受けているものを除く喫煙被験者に対する前記有効用量が1010コロニー形成単位(colony forming unit;CFU)/60kg・bw/日間~1012CFU/60kg・bw/日間であるタバコ嗜癖性の低下用の経口組成物。
- 前記経口組成物は、前記喫煙被験者に、25日間~30日間である投与時間をかけて投与される請求項9に記載のタバコ嗜癖性の低下用の経口組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW110139393A TWI837529B (zh) | 2021-10-22 | 2021-10-22 | 發酵乳桿菌gkf3用於製備降低菸癮之口服組成物的用途 |
TW110139393 | 2021-10-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023063198A JP2023063198A (ja) | 2023-05-09 |
JP7344269B2 true JP7344269B2 (ja) | 2023-09-13 |
Family
ID=86055336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021202524A Active JP7344269B2 (ja) | 2021-10-22 | 2021-12-14 | タバコ嗜癖性の低下用の経口組成物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US11752177B2 (ja) |
JP (1) | JP7344269B2 (ja) |
KR (1) | KR20230057906A (ja) |
TW (1) | TWI837529B (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019202033A1 (en) | 2018-04-18 | 2019-10-24 | Danstar Ferment Ag | Method for alleviating tobacco or nicotine withdrawal symptoms |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0709162D0 (en) * | 2007-05-11 | 2007-06-20 | Jagotec Ag | Dosage foam |
CN105891357B (zh) * | 2016-04-05 | 2018-08-03 | 中国烟草总公司郑州烟草研究院 | 一种动态示踪监测动物体内烟碱及其代谢物的分析方法 |
TWI731279B (zh) * | 2018-11-21 | 2021-06-21 | 葡萄王生技股份有限公司 | 發酵乳桿菌gkf3、含其之組合物及改善精神失調之用途 |
-
2021
- 2021-10-22 TW TW110139393A patent/TWI837529B/zh active
- 2021-12-14 KR KR1020210179034A patent/KR20230057906A/ko not_active Application Discontinuation
- 2021-12-14 JP JP2021202524A patent/JP7344269B2/ja active Active
- 2021-12-17 US US17/554,626 patent/US11752177B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019202033A1 (en) | 2018-04-18 | 2019-10-24 | Danstar Ferment Ag | Method for alleviating tobacco or nicotine withdrawal symptoms |
Non-Patent Citations (2)
Title |
---|
Int J Curr Microbiol App Sci,2016年,Vol.5, No.12,p.365-369 |
Int J Curr Microbiol App Sci,2019年,Vol.8, No.7,p.1193-1200 |
Also Published As
Publication number | Publication date |
---|---|
JP2023063198A (ja) | 2023-05-09 |
KR20230057906A (ko) | 2023-05-02 |
TWI837529B (zh) | 2024-04-01 |
US20230128854A1 (en) | 2023-04-27 |
US11752177B2 (en) | 2023-09-12 |
TW202317161A (zh) | 2023-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4850715B2 (ja) | 乳酸産生菌及び肺機能 | |
US8246946B2 (en) | Treatment of bipolar disorder utilizing anti-fungal compositions | |
US11253556B2 (en) | Lactobacillus fermentum GKF3, composition comprising the strain and method for improving psychataxia using the same | |
WO2008031438A2 (en) | Treatment of asthma, eczema and/or allergy using non-pathogenic organisms | |
EP3781185B1 (en) | Method for alleviating tobacco or nicotine withdrawal symptoms | |
US11865147B2 (en) | Methods for reducing purine content and alleviating disorder of uric acid metabolism | |
RU2725883C2 (ru) | Композиция для сокращения выработки кишечного газа | |
US20130022577A1 (en) | Probiotic compositions useful for treatment of bipolar disorder | |
LU502579B1 (en) | Bifidobacterium lactis for relieving constipation and application thereof | |
CN107206034A (zh) | 包含双歧杆菌的免疫调节组合物 | |
JP2023037613A (ja) | 乳酸菌含有組成物 | |
CN116987608A (zh) | 一种益生菌组合物及其在制备抑郁症并发腹泻型肠易激综合症药物中的应用 | |
JP7344269B2 (ja) | タバコ嗜癖性の低下用の経口組成物 | |
CN117645941A (zh) | 一种通过同时降解尿酸和嘌呤核苷缓解高尿酸血症的发酵粘液乳杆菌及其应用 | |
CN116751726A (zh) | 一株具有上调脑源性神经营养因子表达的凝结魏茨曼氏菌mat411及其应用 | |
CN112566648A (zh) | 包含细菌菌株的组合物 | |
CN116076729A (zh) | 一种组合物以及含有该组合物的食品和药品 | |
CN115998776A (zh) | 发酵乳杆菌gkf3用于制备降低烟瘾之口服组成物的用途 | |
EP2323675B1 (en) | Compositions comprising lactobacillus casei cncm i-1518 (dn-114001) for prevention or treatment of an upper respiratory tract infection in smokers | |
CN111560335A (zh) | 一株用于缓解哮喘的乳双歧杆菌及其应用 | |
CN112458004B (zh) | 一种动物双歧杆菌乳亚种bp026及其应用 | |
JP7361752B2 (ja) | 過活動膀胱関連症状の緩和用の複合プロバイオティクス組成物 | |
CN112654358A (zh) | 用于缓解肠易激综合征和用于缓解其它胃肠道疾病的乳酸杆菌组合 | |
CN114574405B (zh) | 植物乳杆菌菌株wka86及其在制备防治口臭制品方面的用途与制品 | |
JP2022105169A (ja) | 細菌株を含む組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221212 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230329 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230522 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230622 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230807 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230901 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7344269 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |